Skip to main content
ZNTL
NASDAQ Life Sciences

Walters Group Buys $15.2M in Zentalis Offering, Stake Rises to 17.8M Shares

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$3.82
Mkt Cap
$273.787M
52W Low
$1.212
52W High
$6.95
52W Position info
215% above low
Off High info
45% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

ZNTL has more than doubled off its 52-week low of $1.212.

Summary

The Walters Group, a 10% owner of Zentalis Pharmaceuticals, acquired 4,335,000 shares at $3.50 per share for $15.2 million in the company's recent public offering, raising its stake to 17.8 million shares.


Key Events · Ownership and Investor Activity · ZNTL

  • Walters Group Buys $15.2M in Offering

    The Walters Group purchased 4,335,000 shares at $3.50 per share for $15,172,500 in the company's public offering priced on August 14, 2026.

  • Stake Increases to 17.8M Shares

    Post-transaction holdings total 17,844,973 shares, representing a significant ownership position.

  • Offering Context

    The purchase is part of the 23 million share offering priced at $3.50 per share, which raised approximately $75.1 million in net proceeds.

  • Insider Participation

    The Walters Group is a 10% owner, and this purchase demonstrates continued commitment from a major shareholder.


Analysis · ZNTL · Life Sciences

The Walters Group, a 10% owner, purchased 4,335,000 shares at $3.50 per share for $15,172,500 in the company's recent public offering. This increases its total holdings to 17,844,973 shares. The purchase represents a significant commitment from a major shareholder, though it is part of the previously announced offering rather than a new open-market buy.

How filings like this one have moved

In the 30 days to Aug 24, 2026, 29.4% of the 2796 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.03%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ZNTL was trading at $3.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $273.8M. The 52-week trading range was $1.21 to $6.95. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ZNTL - Latest Insights

ZNTL
Aug 14, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.54
Real-time Price: $3.84 info
Change: +$0.3001 (+8%) info
Market Cap: $362.12M info
ZNTL
Aug 14, 2026, 4:09 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $3.54
Real-time Price: $3.84 info
Change: +$0.3001 (+8%) info
Market Cap: $362.12M info
ZNTL
Aug 14, 2026, 6:37 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $3.69
Real-time Price: $3.84 info
Change: +$0.1501 (+4%) info
Market Cap: $362.12M info
ZNTL
Aug 13, 2026, 10:24 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $3.75
Real-time Price: $3.84 info
Change: +$0.0921 (+2%) info
Market Cap: $362.12M info
ZNTL
Aug 13, 2026, 4:37 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $3.65
Real-time Price: $3.84 info
Change: +$0.1901 (+5%) info
Market Cap: $362.12M info